Neurotransmitter transporters play a key role in depression and neurodegenerative diseases (NDD) such as Alzheimer's and Parkinson's.

• Replaces radioactive assays
• One-step, homogeneous assay format
• Two assay setup

The ability to monitor serotonin, norepinephrine and dopamine neurotransmitter uptake is key to a better understanding of these diseases.

Homogeneous, live-cell fluorescent assay replaces radioactive assays, reducing disposal costs and eliminating safety risks associated with radiolabeled assays. One-step, homogeneous assay format is amenable to automation and high-throughput screening. Two assay setup options offer greater flexibility: endpoint mode for high-throughput applications, or real-time kinetic mode for mechanistic studies.